NIPPON EXPRESS (NEDERLAND) ACQUIRES GDP COMPLIANCE CERTIFICATION FOR COMPANY-OWNED WAREHOUSE

TOKYO, Dec. 8, 2021 /Kyodo JBN-AsiaNet/ --

Nippon Express (Nederland) B.V. (hereinafter "NEN"), a local subsidiary of Nippon Express Co., Ltd., obtained Good Distribution Practice (GDP) certification, effective September 6, for its company-owned warehouse in Schiphol Trade Park near Amsterdam's Schiphol Airport, evidencing its compliance with GDP standards for the proper distribution of pharmaceuticals. Logo: https://kyodonewsprwire.jp/img/202112014248-O2-DvOj4uIB Photo1: Warehouse exterior https://kyodonewsprwire.jp/prwfile/release/M103866/202112014248/_prw_PI1fl_Lv4vEAOc.jpg Photo2: Warehouse interior https://kyodonewsprwire.jp/prwfile/release/M103866/202112014248/_prw_PI3fl_78SFb5Xi.jpg The Netherlands has become home to one of Europe's largest clusters of cutting-edge biotechnology companies, and the country's geographical and tax advantages have encouraged numerous pharmaceutical manufacturers to set up logistics bases there. NEN's warehouse near Schiphol Airport, an import/export gateway for Europe, is fully equipped with dedicated pharmaceutical storage areas boasting temperature-control functions for three temperature ranges -- 15 C to 25 C (constant-temperature storage), 2 C to 8 C (refrigerated storage) and -15 C to -25 C (frozen storage) -- as well as dedicated truck docks, enabling NEN to enhance its pharmaceutical transport services to meet anticipated increases in demand. Nippon Express remains committed to improving its services to meet the increasingly sophisticated and diversified pharmaceutical transport needs of its customers, and the Company will continue to strengthen its efforts on behalf of the pharmaceutical industry, identified as a priority industry in its Medium-term Business Plan. Profile of facility Name: Nippon Express (Nederland) B.V. Schiphol Airport Logistics Centre Address: Contour Avenue 31, 2133 LD Hoofddorp, The Netherlands Nippon Express website: http://www.nipponexpress.com/ Official LinkedIn account: NIPPON EXPRESS GROUP https://www.linkedin.com/company/nippon-express-group/ Source: Nippon Express Co., Ltd. --BERNAMA

KYRIBA ANNOUNCES THE APPOINTMENT OF AN EXECUTIVE ADVISORY BOARD

Kyriba Appoints Four Executive Board Advisors to Stimulate Innovation Plans, Business Agility and Economic Growth


SAN DIEGO, Dec 10 (Bernama-BUSINESS WIRE) -- Kyriba Corp. (“the Company”), a global leader of cloud-based finance and IT solutions, announced today the creation of its Executive Advisory Board (“the Board”) comprised of globally recognized leaders who bring a depth of experience and leadership to the Company. The new Executive Advisory Board will play a key role in accelerating the Company’s innovation plans and propelling its international growth strategy in a constantly evolving global marketplace.

The members of the Global Executive Advisory Board, who can be credited with transforming some of the largest and most trusted brands in the world as Deloitte, HSBC and SAP, include:

• Jim Moffatt, former Global Consulting CEO at Deloitte, brings more than 33 years of Senior Leadership experience at Deloitte
• Philippe Henry, former Head of EMEA Global Banking at HSBC with 35 years in transformational leadership in banking and finance. Currently, CEO of Dewenson Partners, a Management Consulting & Venture Capital company
• Brian Shniderman, US CEO & Global Chief Strategy Officer at Openpay, brings 34 years of experience in the payments and fintech advisory industry
• Chakib Bouhdary, former President of SAP Ariba, with more than 30 years of multi-industry experience

In the post-COVID context, Financial Departments are increasingly turning to APIs, AI and data management technologies to increase their visibility on cash, drive strategic value and become trusted enterprise partners. The Board’s mission is to provide strategic guidance to Kyriba business leaders on new growth drivers and bring to market solutions, practices and new talent capabilities as the sector matures and digitalizes.

“The demand for novel applications and practices stemming from the combined use of APIs, AI and data management from our clients creates a unique opportunity to think about how we can better support corporate Finance departments. It also opens the path to new growth drivers,” said Jean-Luc Robert, Chairman and CEO of Kyriba. “I am both honored and thrilled to work with Jim, Philippe, Brian, and Chakib. I am confident they will play a valuable role in guiding our strategic decisions and our innovation plans to help us stimulate our business in any context.”

Jim Moffatt will serve as the Chair of the Advisory Board and will be responsible to execute the Board’s charter and support the expansion of the Board.

"Kyriba has transformed the way multinational CFOs, Finance and IT leaders unlock value creation through a unified liquidity management solution,” said Jim Moffatt. “I am excited to share my perspectives with Jean-Luc and the executive team at Kyriba, and to join the Company's Executive Advisory Board."

For more information about Kyriba, please go to Kyriba.com.

About Kyriba Corp.:

Kyriba is a secure, scalable open platform that leverages artificial intelligence, automates payments workflows, and enables thousands of multinational corporations and banks to optimize liquidity, protect against loss from fraud and financial risk, and reduce operational costs. With more than 2,000 clients worldwide, including 25 percent of Fortune 500 and Eurostoxx 50 companies, Kyriba empowers CFOs, Treasurers, and their IT counterparts to transform how they optimize liquidity and manage risk, managing more than 1.3 billion bank transactions per year, and 200 million payments into 140 countries annually.

Kyriba is headquartered in San Diego, with offices in Dubai, Frankfurt, London, Minsk, Paris, Shanghai, Singapore, Tokyo, Warsaw and other major locations. For more information, visit www.kyriba.com.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20211209005652/en/

Contact

Corporate Media Contact:
Daniel Shaffer
dshaffer@kryiba.com
+1858-263-2219

Source : Kyriba Corp.

STANDARD CHARTERED SELECTS PLANVIEW'S PORTFOLIO MANAGEMENT SOLUTION TO CONNECT WORK ACROSS THE BUSINESS

Partnership provides the visibility, transparency, and flexibility needed to propel the banking group into a new era of digitalization and client service

AUSTIN, Texas, Dec 8 (Bernama-BUSINESS WIRE) -- Planview, a global leader in Portfolio Management and Work Management solutions, today announces that Standard Chartered, a leading international banking group, has selected Planview as the organization's enterprise-wide solution to manage the Bank’s portfolio of technology projects. This partnership offers teams at Standard Chartered the flexibility to manage projects across waterfall, agile, hybrid governance models, while offering critical visibility and consolidated reporting to all levels of management.

Adopting Planview's industry-leading technology will enable Standard Chartered to deliver on core strategic priorities, transitioning to new ways of working and implementing platforms that enable its teams to deliver new products and features to meet clients' changing needs.

“As a leading global financial institution, Standard Chartered needed visibility and transparency into its business to help understand and shape its path forward in a dynamic industry, and we were excited to be selected as the partner best fit for the job,” said Razat Gaurav, CEO, Planview. “By connecting work across various governance models with the company’s most important initiatives, we will help enable Standard Chartered to unlock a new, flexible and agile future that has a consolidated view into how the banking group delivers services to meet its clients’ needs.”

The new Planview solution will help manage all internal projects–both traditional and agile initiatives. By using Standard Chartered's internal resources, timelines, financials and more, Planview will support the organization both on an individual and project-level basis, as well as a roll-up aggregation of its overall portfolio.

To learn more about Planview’s full spectrum of Portfolio Management and Work Management solutions, please visit https://www.planview.com. 

About Planview

Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions create an organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,000 employees supporting 4,000 customers and 2.4 million users worldwide. For more information, visit www.planview.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005697/en/ 

Contact

Leslie Marcotte, lmarcotte@planview.com 

Source : Planview

--BERNAMA

AM BEST AFFIRMS CREDIT RATINGS OF FUBON INSURANCE VIETNAM CO., LTD.

SINGAPORE, Dec 10 (Bernama-BUSINESS WIRE) -- AM Best has affirmed the Financial Strength Rating of B++ (Good) and the Long-Term Issuer Credit Rating of “bbb+” (Good) of Fubon Insurance Vietnam Co., Ltd. (Fubon Vietnam) (Vietnam). The outlook of these Credit Ratings (ratings) is stable.

The ratings reflect Fubon Vietnam’s balance sheet strength, which AM Best assesses as strong, as well as its adequate operating performance, limited business profile and appropriate enterprise risk management. The ratings also factor in rating enhancement from its parent company, Fubon Insurance Co., Ltd. (Fubon Insurance) (Taiwan).

Fubon Vietnam’s balance sheet strength assessment is underpinned by its risk-adjusted capitalisation that is expected to remain at the strongest level over the medium term, as measured by Best’s Capital Adequacy Ratio (BCAR). Favorable balance sheet considerations include the company’s low net underwriting leverage, a conservative investment portfolio consisting solely of cash, and term deposits. In addition, the company is viewed to have good financial flexibility supported by its parent, Fubon Insurance. AM Best considers the company’s high third-party reinsurance usage and dependence as an offsetting balance sheet factor, albeit that reinsurance counterparty risks are mitigated by reinsurance assets of typically good credit quality.

AM Best views the company’s operating performance as adequate, as evidenced by a five-year average return-on-equity ratio of 6.3% (2016-2020). The company’s underwriting performance continues to be supported by its commercial insurance portfolio, more notably property insurance, while being offset by poorer performing lines including personal accident and health insurance. The expense ratio has reduced in 2020 driven by an increasing business scale and higher premium retention. In addition, reinsurance commissions remained a good contribution to overall earnings. Investment income is a key contributor to overall earnings, although it is expected to be constrained given low domestic interest rates over the near term.

AM Best assesses Fubon Vietnam’s business profile as limited. Fubon Vietnam is a small-sized non-life insurer in Vietnam, with a market share of less than 1%, as measured by 2020 gross premium written (GPW). Although the company is considered a small size player within Vietnam, it has a good market position in its core business segment of property insurance. The company derives a significant proportion of business from Taiwanese corporations within its domestic market, whereby its business profile benefits from the brand recognition of its parent, Fubon Insurance, a market leading non-life insurer incorporated in Taiwan. The company’s underwriting portfolio exhibits a high concentration to property insurance, which accounted for over 70% of 2020 GPW, as well as a concentration to the domestic non-life market.

The company’s ratings incorporate rating enhancement from its ownership and integration with Fubon Insurance. Fubon Vietnam benefits from its common branding and affiliation with Fubon Insurance, and receives implicit and explicit support from its parent. The company is considered important in supporting the group’s regional business growth across Southeast Asia over the medium to long term.

Ratings are communicated to rated entities prior to publication. Unless stated otherwise, the ratings were not amended subsequent to that communication.

This press release relates to Credit Ratings that have been published on AM Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best’s Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings. For information on the proper use of Best’s Credit Ratings, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments.

AM Best is a global credit rating agency, news publisher and data analytics provider specialising in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

Copyright © 2021 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20211209005730/en/

Contact

Chris Lim
Senior Financial Analyst
+65 6303 5018
chris.lim@ambest.com

Yuan Tian
Senior Financial Analyst
+65 6303 5016
yuan.tian@ambest.com

Christopher Sharkey
Manager, Public Relations
+1 908 439 2200, ext. 5159
christopher.sharkey@ambest.com

Jim Peavy
Director, Communications
+1 908 439 2200, ext. 5644
james.peavy@ambest.com

Source : AM Best

LEADING OTT PLAYERS IN SOUTHEAST ASIA ANNOUNCE SUPPORT FOR UNIFIED ID 2.0

New identity solution expands in the region with backing from key OTT platforms


SINGAPORE, Dec 9 (Bernama-BUSINESS WIRE) -- Global advertising leader, The Trade Desk (NASDAQ: TTD), today announced that the Unified ID 2.0 initiative has expanded into the Southeast Asia market as leading over-the-top (OTT) players announce their support. Initially developed by The Trade Desk, Unified ID 2.0 is a new, privacy-conscious identifier built from hashed and encrypted email addresses. Designed from the consumer’s perspective, Unified ID 2.0 is a new industry-wide approach to internet identity that aims to preserve the value of relevant advertising, while putting control for consumers and privacy at the forefront.

Leading OTT players in Southeast Asia have prioritized the use of Unified ID 2.0 to preserve the free flow of content in exchange for relevant advertising including regional OTT platforms iQiyi, TrueID, WeTV/iflix; FPT Play and VTV Giai Tri (VTVE) in Vietnam; and Indonesia’s largest local OTT platform, Vidio. Unified ID 2.0 empowers publishers to pseudonymize their first-party data and allows for advertisers to optimize their first-party customer data and measure their media investments without third-party cookies.

Unified ID 2.0 has already gained widespread adoption across the media industry globally, including from data companies and major advertising holding companies. It’s also seen momentum with publishers by providing an opportunity for them to further prove the value exchange of the open internet. Key benefits for publishers may include:

• Strategy – Publishers can continue to match advertiser audiences, managing frequency and measuring outcomes in order to maintain a sustainable strategy
• Independence – An open identifier means that publisher monetization will be less reliant on the actions of individual browsers and device makers
• Better Consumer Experience – Consumer control will make it easier for publishers to build and maintain trust with their users. More effective targeting will also help enable lighter ad loads and a better overall consumer experience

“The collaboration around Unified ID 2.0 allows digital publishers to participate in this industry-wide initiative to pioneer a new approach to identity. We are especially thrilled to see momentum from OTT players in the Southeast Asia region,” said Bihao Pan, Lead Senior Director, Inventory Partnerships, The Trade Desk. “Together, we are all creating a better, more privacy-conscious open internet across devices and platforms. We’re excited for continued adoption as the ID scales and grows further, while aiming to give consumers greater transparency and control.”

For more information about Unified ID 2.0, please visit the Unified ID solution site.

About Unified ID 2.0

Unified ID 2.0 is a next-generation identity solution that is an open-source digital framework. With initial development led by The Trade Desk, Unified ID 2.0 is the result of a broad collaboration of publishers, buyers and technology providers across the industry. It serves as an alternative to third-party cookies that aims to improve consumer transparency, privacy and control while preserving the value exchange of relevant advertising across channels and devices.

Prebid.org, the independent organization designed to ensure and promote fair and transparent marketplaces across the industry, has agreed to serve as operator of Unified ID 2.0.

About The Trade Desk

The Trade Desk™ is a technology company that empowers buyers of advertising. Through its self-service, cloud-based platform, ad buyers can create, manage, and optimize digital advertising campaigns across ad formats and devices. Integrations with major data, inventory, and publisher partners ensure maximum reach and decisioning capabilities, and enterprise APIs enable custom development on top of the platform. Headquartered in Ventura, CA, The Trade Desk has offices across North America, Europe, and Asia Pacific. To learn more, visit thetradedesk.com or follow us on Facebook, Twitter, and LinkedIn.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20211208005804/en/

Contact

Media contact
Shaw Wun Lim
The Trade Desk
shawwun.lim@thetradedesk.com

Source : The Trade Desk

PRESTIGE BIOPHARMA AND DR. REDDY'S ANNOUNCE PARTNERSHIP TO COMMERCIALIZE TRASTUZUMAB BIOSIMILAR IN SELECT COUNTRIES IN LATIN AMERICA AND SOUTHEAST ASIA

SINGAPORE & HYDERABAD, India, Dec 9 (Bernama-BUSINESS WIRE) -- Prestige BioPharma Ltd. (KRX: 950210) and Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Reddy’s”) today announced that the two companies have entered into a binding agreement for an exclusive partnership for the supply and commercialization of Prestige BioPharma’s proposed trastuzumab biosimilar in select countries in Latin America and Southeast Asia.

Prestige BioPharma’s trastuzumab (HD201) is a proposed biosimilar to Roche’s Herceptin® and can be prescribed for the treatment of HER2 positive breast and metastatic gastric cancer. Trastuzumab targets human epidermal growth factor 2 (HER2). In some types of cancer cells, HER2 is overexpressed and stimulates the growth of the cancer cells. Trastuzumab works by selectively binding to HER2, thereby stopping the growth of these cancer cells.

The license agreement grants Dr. Reddy’s the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia. Under this partnership, Prestige BioPharma will be responsible for sustainable commercial supply of HD201 from its manufacturing facilities in Osong, South Korea, while Dr. Reddy’s will be responsible for local registrations, marketing and sales in the licensed territories.

Lisa S. Park, CEO of Prestige BioPharma, commented: “We are delighted to establish a partnership with Dr. Reddy’s for key Latin American and Southeast Asian markets. Dr. Reddy’s is the ideal partner to commercialize our lead biosimilar in these territories. With this collaboration, we look forward to further strengthening the value of our biosimilar programs in global markets.”

M.V. Ramana, CEO – Branded Markets (India & Emerging Markets), Dr. Reddy’s, said: “In keeping with our purpose of accelerating access to affordable and innovative medicines, we are happy to bring this life-saving drug to patients in need. Our partnership with Prestige BioPharma will help us combine their established expertise in the area of biosimilars with our commercial strengths and growth ambition in these markets. This is in line with our stated intention to create a portfolio of oncology products and expand our biosimilar offerings in Emerging Markets.”

About Prestige BioPharma Limited:
PRESTIGE BIOPHARMA LTD (PBP) is a Singapore-based biopharmaceutical company with operations in USA and Korea, specialising in the discovery and development of biosimilars, novel antibodies and vaccines. PBP strives to become a global innovator through the development of first-in-class mAbs including PBP1510 anti-PAUF mAb for pancreatic cancer that recently obtained orphan designation from FDA, EMA and MFDS. PBP's rich portfolio of biosimilars in various stages including HD204 bevacizumab in global Phase 3, PBP1502 adalimumab in Phase 1 and others, is aimed to provide affordable quality medicines to those who need. PBP’s business also includes alliance vaccine development and production, starting with the partnered commercial production of COVID-19 vaccines. For more information, please visit www.prestigebiopharma.com.

About Dr. Reddy’s:
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its businesses, Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20211208006176/en/

Contact

Prestige BioPharma Limited

Investor Relations
Bumjoon Kim
Bumjoon.kim@pbpsg.com

Corporate Communication
Yujin Suh
yujin.suh@pgpsg.com

Dr. Reddy’s Laboratories Ltd.

Investor Relations
Amit Agarwal
amita@drreddys.com

Corporate Communication
Usha Iyer
ushaiyer@drreddys.com

Source : Dr. Reddy’s Laboratories Ltd.

Adagene Presents Clinical Data Demonstrating Cold Tumour Efficacy

KUALA LUMPUR, Dec 7  -- Adagene Inc (Adagene) has announced clinical data on its anti-CTLA-4 monoclonal antibody, ADG116, and anti-CD137 agonist, ADG106, in two poster presentations at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021, to be held virtually and in Geneva, Switzerland from Dec 8 to 11.

In the first presentation of results from an ongoing dose-escalation trial of monotherapy in patients with advanced metastatic tumours, ADG116 demonstrated a strong safety profile and early signals of efficacy, including dose-dependent T-cell activation and tumour suppression in treatment-resistant ‘cold’ and ‘warm’ tumours such as pancreatic, ovarian and renal cell cancers.

On the findings, Dr Gary Richardson, OAM, MBBS, FRACP, Group Director at Cabrini Health Research, Director at Szalmuk Family Department of Medical Oncology and Professor of Medicine at Monash University, Australia said in a statement:

“These encouraging clinical data demonstrate the promising safety profile of ADG116 monotherapy in patients with advanced solid tumours across 15 different tumour types, the majority of which are resistant to standard therapy.

The most exciting thing about these results is that we have also seen the early signals of efficacy in ‘cold’ tumors such as pancreatic and certain gynecological cancers, which do not respond to current immunotherapies.

“We want to see this type of unique activity, which suggests that this treatment may look different and potentially better than the options we have available today.”

For more information, visit: https://investor.adagene.com.

-- BERNAMA